

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-8.

9. (Currently amended) A method for treating a B-cell disorder in a ~~horse, cattle, sheep, goat, llama, alpaca, pig,~~ dog[[.]] or cat, consisting of administering to the ~~horse, cattle, sheep, goat, llama, alpaca, pig,~~ dog[[.]] or cat having said disorder a therapeutic composition consisting of an anti-HLA-DR antibody component and a cytotoxic drug, an immunosuppressive drug, or an immunomodulator, each in a pharmaceutically acceptable carrier, wherein said B-cell disorder is a ~~malignancy~~ lymphoma or leukemia.

10-13. Canceled.

14. (Currently amended) The method of claim [[1]] 9, additionally comprising administering a cytokine.

15. (Currently amended) The method of claim [[1]] 9, additionally comprising administering a chemotherapeutic agent.

16-24. Canceled.

25. (Currently amended) The method of claim [[1]] 9, wherein said therapeutic composition comprises a combination of two or more naked antibodies against different epitopes of the same antigen or against different antigens associated with one cell type.

26. (Currently amended) The method of claim [[1]] 9, wherein said therapeutic composition comprises a combination of a naked antibody and a radiolabeled immunoconjugate.

27. (Currently amended) The method of claim [[1]] 9, wherein said therapeutic composition comprises a combination of a naked antibody and a toxin immunoconjugate.

28. (Original) The method of claim 27, wherein said toxin immunoconjugate comprises an RNase.

29. (Original) The method of claim 28, wherein said RNase is a recombinant RNase.

30-31. Canceled.

32. (Currently amended) The method of claim [[1]] 9, wherein the antibody component comprises a multispecific antibody.

33. (Currently amended) The method of claim [[1]] 9, wherein the antibody component comprises a bispecific antibody.

34. (Previously presented) The method of claim 33, wherein said antibody component comprises an arm that is specific for a low-molecular weight hapten and wherein a low-molecular weight hapten with an attached therapeutic agent is administered after the antibody component is administered and has bound to the antigen or epitope.

35. (Original) The method of claim 34, wherein the therapeutic agent is a radionuclide.

36. (Original) The method of claim 34, wherein the therapeutic agent is a drug.

37. (Currently amended) The method of claim [[1]] 9, wherein said therapeutic composition comprises a combination of a chemotherapeutic agent and an antibody component labeled with a therapeutic radionuclide.

38-40. Canceled.

41. (Currently amended) The method of claim [[1]] 9, wherein said therapeutic composition comprises a combination of naked antibodies.

42. (Original) The method of claim 41, wherein said therapeutic composition comprises a fusion protein of said combination of antibodies.

43. (Currently amended) The method of claim [[1]] 9, wherein said therapeutic composition comprises a combination of naked antibodies and immunoconjugates.

44. (Currently amended) The method claim [[1]] 9, wherein said therapeutic composition comprises a hybrid antibody that binds to more than one antigen.

45. Canceled.

46. (Currently amended) The method of claim [[1]] 9, additionally comprising administering radiation therapy.

47. Canceled.

48. (Currently amended) The method of claim [[1]] 9, additionally comprising administering an immunosuppressive agent.

49-51. Canceled.

52. (Currently amended) The method of claim [[1]] 9, wherein said antibody component is a naked anti-HLA-DR antibody.

53-54. Canceled.

55. (Currently amended) The method of claim [[54]] 9, wherein said animal is ~~a cat or a dog~~.

56. Canceled.

57. (Currently amended) The method of claim [[54]] 9, wherein said lymphoma is a B-cell lymphoma.

58. Canceled.

59. (Currently amended) The method of claim [[54]] 9, wherein said lymphoma is a B-cell leukemia.

60. (Currently amended) A method for treating a B-cell ~~disorder~~ leukemia or lymphoma in a ~~horse, cattle, sheep, goat, llama, alpaca, pig, dog~~[[,]] or cat, consisting of administering to the ~~horse, cattle, sheep, goat, llama, alpaca, pig, dog~~[[,]] or cat having said ~~disorder~~ leukemia or lymphoma a therapeutic composition consisting of an anti-HLA-DR antibody component and, optionally, a cytotoxic drug, an immunosuppressive drug, or an immunomodulator, each in a pharmaceutically acceptable carrier.

61. (Currently amended) The method of claim [[62]] 60, wherein said anti-HLA-DR antibody is a naked antibody.

62-63. Canceled.